Saturday 17 October 2026
Export HAE’s income statement to Excel — free account
Haemonetics Corporation
HAE Healthcare Medical Devices
Haemonetics Corporation’s revenue for fiscal 2026 (year ended March 2026) was $1.3 billion, down 1.97% from fiscal 2025. In the quarter to June 2026, revenue grew 5.60%, EPS grew 2.86%, free cash flow grew 220.4% and total debt rose 27.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
118.28
3.01
−2.48%
Follow HAE
| Mar '17 | Mar '18 | Mar '19 | Mar '20 | Mar '21 | Mar '22 | Mar '23 | Mar '24 | Mar '25 | Mar '26 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
5 | 7 | 7 | 8 | 5 | 5 | 8 | 7 | 6 | 6 |
P/E ratio |
0.00 | 83.91 | 85.48 | 66.00 | 71.16 | 75.26 | 36.78 | 37.03 | 19.03 | 27.76 |
Altman Z-Score |
3.79 | 6.09 | 5.93 | 5.91 | 4.16 | 2.78 | 3.63 | 3.43 | 2.41 | 2.21 |
P/S ratio |
2.36 | 4.21 | 4.78 | 5.11 | 6.46 | 3.25 | 3.60 | 3.28 | 2.35 | 1.99 |
Altman Z″-Score (non-manufacturers) |
3.80 | 3.36 | 3.76 | 3.36 | 2.91 | 2.46 | 3.49 | 3.26 | 2.56 | 2.85 |
P/FCF ratio |
24.19 | 25.67 | 107.23 | 40.02 | 76.47 | 41.49 | 50.42 | 29.56 | 19.30 | 10.16 |
Beneish M-Score |
(3.20) | (3.19) | (2.73) | (2.92) | (2.57) | (2.71) | (2.73) | (2.42) | (2.64) | (2.81) |
P/Operating CF |
60.45 | 66.06 | 224.11 | 108.86 | 3,637.28 | 47.42 | 52.79 | 67.09 | 27.44 | 37.48 |
P/B ratio |
2.83 | 5.06 | 6.93 | 8.60 | 7.69 | 4.31 | 5.14 | 4.48 | 3.90 | 3.34 |
Price to Tangible BV |
5.95 | 9.90 | 14.04 | 20.76 | 0.00 | 0.00 | 55.30 | 0.00 | 0.00 | 0.00 |
EV/Sales |
2.49 | 4.08 | 4.94 | 5.28 | 7.04 | 3.55 | 4.00 | 3.76 | 2.80 | 2.72 |
EV/EBITDA |
31.33 | 25.35 | 24.76 | 24.37 | 35.08 | 19.39 | 18.74 | 18.53 | 10.82 | 13.25 |
EV/Operating CF |
13.80 | 16.73 | 30.00 | 32.99 | 56.29 | 20.48 | 17.11 | 27.06 | 20.98 | 12.39 |
EV/FCF |
25.51 | 24.85 | 110.78 | 41.35 | 83.24 | 45.35 | 56.06 | 33.82 | 23.01 | 13.88 |
Quick Ratio |
1.38 | 0.86 | 1.50 | 1.10 | 1.26 | 0.95 | 1.84 | 1.28 | 0.88 | 1.64 |
Current Ratio |
2.42 | 1.35 | 2.44 | 2.20 | 2.74 | 1.71 | 3.06 | 2.56 | 1.62 | 2.95 |
Net Debt/EBITDA |
1.62 | (0.83) | 0.79 | 0.79 | 2.85 | 1.65 | 1.88 | 2.33 | 1.74 | 3.55 |
Debt/Assets |
20.47% | 4.80% | 25.30% | 24.11% | 37.95% | 30.08% | 38.98% | 36.33% | 37.59% | 50.90% |
Debt/Equity |
0.34 | 0.08 | 0.48 | 0.52 | 0.94 | 0.75 | 0.92 | 0.83 | 1.12 | 1.53 |
Asset Turnover |
0.69 | 0.73 | 0.77 | 0.78 | 0.56 | 0.54 | 0.62 | 0.63 | 0.59 | 0.55 |
Operating CF/Net income |
(6.08) | 4.84 | 2.90 | 2.07 | 1.37 | 3.97 | 2.37 | 1.55 | 1.08 | 3.01 |
Capex/Depreciation |
(0.82) | (0.81) | (1.06) | (0.29) | (0.42) | (0.93) | (2.03) | (0.36) | (0.12) | (0.27) |
Interest Coverage |
(2.39) | 12.41 | 8.43 | 6.38 | 5.33 | 4.72 | 10.67 | 12.67 | 22.76 | 5.46 |
| (3.60%) | 6.11% | 7.75% | 12.20% | 12.05% | 5.86% | 14.72% | 13.22% | 18.83% | 12.03% | |
| (2.05%) | 3.68% | 4.38% | 6.02% | 5.15% | 2.36% | 6.08% | 5.69% | 7.22% | 4.02% | |
ROIC |
(1.42%) | 5.56% | 6.36% | 8.55% | 4.56% | 4.81% | 7.57% | 6.53% | 9.66% | 5.53% |
Return on Tangible Assets |
(4.22%) | 9.72% | 8.04% | 13.14% | 12.08% | 7.58% | 13.92% | 15.07% | 26.16% | 11.34% |
Average Days of Receivables |
62.89 | 61.06 | 69.80 | 61.00 | 53.49 | 58.57 | 55.95 | 57.60 | 54.36 | 59.33 |
Research and Development Expense of Revenue |
4.24% | 4.34% | 3.69% | 3.12% | 3.77% | 4.71% | 4.29% | 4.16% | 4.61% | 4.48% |
Selling, General and Administrative Expense of Revenue |
34.05% | 35.02% | 28.26% | 28.53% | 31.62% | 34.25% | 32.23% | 32.83% | 32.10% | 33.16% |
Intangible Assets out of Total Assets |
0.31 | 0.30 | 0.27 | 0.27 | 0.46 | 0.42 | 0.38 | 0.44 | 0.43 | 0.46 |
Share Based Compensation of Revenue |
1.03% | 1.44% | 1.78% | 2.07% | 2.93% | 2.45% | 2.19% | 2.16% | 2.18% | 2.54% |
Graham Net Nets |
0.01 | 0.01 | (0.01) | (0.02) | (0.07) | (0.11) | (0.08) | (0.11) | (0.22) | (0.29) |
Graham Number |
0.00 | 16.61 | 17.50 | 19.84 | 22.51 | 16.66 | 28.56 | 31.23 | 35.01 | 27.77 |
Earnings Yield |
(1.23%) | 1.19% | 1.17% | 1.52% | 1.41% | 1.33% | 2.72% | 2.70% | 5.26% | 3.60% |
Free Cash Flow Yield |
4.13% | 3.90% | 0.93% | 2.50% | 1.31% | 2.41% | 1.98% | 3.38% | 5.18% | 9.85% |
Revenue per Share |
17.20 | 17.13 | 18.78 | 19.50 | 17.17 | 19.46 | 23.01 | 25.82 | 27.04 | 28.28 |
Operating CF per Share |
3.10 | 4.18 | 3.09 | 3.12 | 2.15 | 3.37 | 5.38 | 3.58 | 3.61 | 6.22 |
Capex per Share |
(1.42) | (1.37) | (2.25) | (0.63) | (0.69) | (1.85) | (3.74) | (0.72) | (0.32) | (0.67) |
Free Cash Flow per Share |
1.68 | 2.81 | 0.84 | 2.49 | 1.45 | 1.52 | 1.64 | 2.87 | 3.29 | 5.55 |
Cash per Share |
2.71 | 3.42 | 3.29 | 2.71 | 3.79 | 5.08 | 5.60 | 3.53 | 6.10 | 5.20 |
Shareholders Equity per Share |
14.35 | 14.26 | 12.96 | 11.58 | 14.43 | 14.68 | 16.11 | 18.93 | 16.31 | 16.88 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
14.35 | 14.26 | 12.96 | 11.58 | 14.43 | 14.68 | 16.11 | 18.93 | 16.31 | 16.88 |
Free Cash Flow |
86.43 | 148.31 | 43.13 | 126.23 | 73.58 | 77.78 | 83.34 | 145.44 | 165.70 | 261.82 |
Working Capital |
298.85 | 136.47 | 340.36 | 328.82 | 440.05 | 313.77 | 517.91 | 468.52 | 356.86 | 552.28 |
Capital Expenditures |
(73.31) | (72.04) | (116.15) | (31.98) | (35.22) | (94.49) | (189.72) | (36.31) | (16.02) | (31.40) |
Net Current Asset Value |
10.93 | 36.27 | (30.78) | (76.36) | (394.71) | (354.28) | (347.11) | (466.73) | (695.14) | (764.73) |
EV/EBIT |
0.00 | 65.64 | 57.19 | 50.51 | 68.25 | 43.68 | 29.94 | 29.83 | 17.19 | 23.18 |
Capex to Sales |
0.08 | 0.08 | 0.12 | 0.03 | 0.04 | 0.10 | 0.16 | 0.03 | 0.01 | 0.02 |
Price to Operating Income |
0.00 | 67.79 | 55.36 | 48.88 | 62.70 | 39.97 | 26.93 | 26.08 | 14.42 | 16.97 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.28 | 0.27 | 0.32 | 0.44 | 0.39 | 0.39 | 0.30 | 0.32 | 0.46 | 0.38 |
Cash ROIC |
7.63% | 14.95% | 3.72% | 12.26% | 4.56% | 4.96% | 4.49% | 7.51% | 8.09% | 11.58% |
Accounts Receivable Turnover |
5.72 | 5.95 | 5.76 | 5.64 | 5.95 | 6.92 | 6.90 | 6.79 | 6.65 | 6.36 |
Accounts Payable Turnover |
12.28 | 10.02 | 9.27 | 8.83 | 9.36 | 8.98 | 9.05 | 9.00 | 8.72 | 9.26 |
Inventory Turnover |
2.79 | 2.91 | 3.10 | 2.17 | 1.59 | 1.58 | 2.00 | 2.14 | 1.79 | 1.63 |
Average Days of Payables |
30.90 | 41.00 | 42.05 | 36.74 | 38.84 | 43.69 | 42.15 | 43.36 | 39.97 | 34.10 |
Days of Inventory on Hand |
127.22 | 119.29 | 128.96 | 195.75 | 249.15 | 219.31 | 171.03 | 187.49 | 217.82 | 204.64 |
Average Receivables |
154.89 | 151.95 | 168.13 | 175.12 | 146.38 | 143.47 | 169.26 | 192.85 | 204.61 | 209.76 |
Average Payables |
41.32 | 49.12 | 59.31 | 57.05 | 50.51 | 54.33 | 61.15 | 68.64 | 70.18 | 59.03 |
Average Inventory |
181.98 | 168.86 | 177.57 | 232.31 | 296.45 | 307.82 | 276.20 | 288.29 | 341.17 | 335.76 |
Average Assets |
1,278.92 | 1,238.02 | 1,256.05 | 1,270.94 | 1,543.52 | 1,839.83 | 1,897.28 | 2,065.21 | 2,323.27 | 2,423.44 |
Average Common Equity |
730.59 | 746.02 | 710.15 | 627.49 | 659.39 | 740.55 | 783.71 | 888.98 | 890.40 | 808.58 |
Columns are period end dates